| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BiomX Inc.$0.23
-0.06 (-20%)
D 21Pipeline Score Richly Valued Biotech · Clinical
Market Cap
8.28 M
EPS
-24.96
P/E Ratio
-
Value Trade
568.32 K
SEC Financials
Q1 2026Dilution Risk
Operating CF
-5.41 M
Total Assets
3.25 M
Total Liabilities
4.13 M
Equity
-881.00 K
D/E Ratio
12,345
32.96 %
Week
-44.46 %
1 Month
-84.08 %
3 Month
-85.18 %
6 Month
-99.93 %
5 Year
-99.96 %
All Time
Cash Data
Cash Position
1.17 M
Monthly Burn
1.80 M
Runway
0 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
9.80 M
52 Week Range
0.36 - 14.71
% held by Insiders
27.29 %
% held by Institutions
1.54 %
Enterprise Value
25.73 M
Total Shares
6.54 M
Short %
11.04 %
Float Shares
3.70 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BiomX Inc.
244Total events
4Upcoming
71Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 4
Event history 240
Jun 24, 2026
●Oral PresentationPresentation
DFSL to showcase LADAR-based counter-drone solutions at ISC 2026
Apr 24, 2026
Mar 25, 2026
Mar 19, 2026
Mar 19, 2026
Feb 19, 2026
Q1 2026
◆Topline ReadoutBX004Clinical Data
Topline results expected from Phase 2b trial
cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infectionsource ↗
Drug Pipeline Intelligence
D21
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 19%
Micro Cap (rank 739 of 911)
Percentile RankBiomX Inc. faces pipeline headwinds (21/100), with $267M risk-adjusted pipeline value, led by BX002-A in Healthy Volunteers (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BX002-A Monoclonal antibody | Healthy Volunteers | Phase 1 | NCT04737876 | 13% | $126M | COMPLETED | 18 | - | - | Dec 21, 2020 | - | Jan 25, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BX004 Fast TrackOrphan | cystic fibrosis | Phase 2b | 2025-11-25 | improvement in pulmonary function associated with a reduction in P. aeruginosa burden versus placebo in a predefined subgroup of patients with reduced lung function (baseline FEV1<70%) Read More | BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis Read More | |
BX004 Fast TrackOrphan | cystic fibrosis | Phase 2b | 2025-11-25 | improvement in pulmonary function associated with a reduction in P. aeruginosa burden versus placebo in a predefined subgroup of patients with reduced lung function (baseline FEV1<70%) Read More | BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis Read More | |
BX004 Fast TrackOrphan | cystic fibrosis | Phase 2b | 2025-11-25 | improvement in pulmonary function associated with a reduction in P. aeruginosa burden versus placebo in a predefined subgroup of patients with reduced lung function (baseline FEV1<70%) Read More | BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PHGE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PHGE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PHGE▼ -20%today
BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities
BiomX Inc. announced that its subsidiary Zorronet has successfully transitioned to a new advanced data center. This upgrade aims to enhance performance, scalability, and cost efficiency, enabling better real-time AI command-and-control solutions for defense and security. The new facility is integral to Zorronet's modernization efforts and supports its business expansion.
Read more →PHGE▼ -8.4%on this news
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities
BiomX Inc. has signed a non-binding letter of intent to acquire a 60% stake in Tsoock Defense Technologies, a company specializing in security infrastructure. The acquisition aims to enhance BiomX's capabilities in defense and security sectors. Tsoock has shown substantial revenue growth, indicating strong operational performance. However, the transaction is contingent on various approvals and due diligence.
Read more →PHGE▼ -5.3%on this newsshared move
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement
BiomX's subsidiary Zorronet has begun the installation of AI-powered detection systems for Israel Railways, aimed at protecting wildlife and infrastructure. The project follows a successful pilot with a 98% success rate in preventing animal-related incidents. The collaboration is expected to expand as Israel Railways develops its network further.
Read more →PHGE▼ -9.7%on this news· ran to -22% by day 3
BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026
BiomX Inc. announced that its subsidiary DFSL will showcase advanced LADAR-based counter-drone solutions at ISC 2026. The technology boasts high accuracy in detecting UAVs and intruders, aiming to enhance security in various sectors. This event emphasizes BiomX's commitment to developing a robust defense technology portfolio amid growing drone threats.
Read more →PHGE▼ -5.5%on this news· ran to -24% by day 3shared move
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy
BiomX Inc. has updated its strategic focus towards defense technologies, emphasizing its portfolio that includes advanced threat detection systems. The company aims to enhance its operational framework and compliance with NYSE American standards. CEO Michael Oster highlighted the importance of adapting to new challenges posed by UAVs and autonomous systems in security. The updated presentation showcases the leadership team's relevant experience in the defense sector.
Read more →PHGE▼ -24.2%on this news
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance
BiomX Inc. announced that its plan to regain compliance with NYSE American listing standards has been accepted, allowing until September 25, 2027, for compliance. The company had previously been notified of non-compliance due to a stockholders' deficit and ongoing losses. During this period, the stock will remain listed, subject to compliance with the plan.
Read more →PHGE▲ +10.6%on this newsshared move
BiomX: Zorronet’s AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events
BiomX Inc. has published a review by Zorronet's CEO, Idan Wasserman, emphasizing the need for AI security systems to evolve beyond mere detection to understanding context. The review highlights challenges faced during large events, advocating for systems that can interpret behaviors based on cultural and situational contexts. This shift aims to enhance the effectiveness of security operations.
Read more →PHGE▼ -9.2%on this news· ran to -25% by day 3
Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit
BiomX Inc. has appointed Prof. Gabby Sarusi as a Strategic Advisor to enhance its presence in defense and security sectors. With a rich background in technology development and operational leadership, Prof. Sarusi will assist in evaluating new opportunities and advancing the company's growth strategy. His experience in advanced sensing technologies will be pivotal for BiomX's mission.
Read more →PHGEBiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
BiomX Inc. has appointed Roy Timor-Rousso as Chief Business Officer to enhance its leadership in defense and security operations. With extensive military and technology experience, Timor-Rousso is expected to drive the company's focus on autonomous technologies and critical infrastructure protection. His appointment reflects BiomX's commitment to scaling operations and addressing emerging threats in the defense sector.
Read more →PHGE▼ -5.7%on this news
BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
BiomX Inc. has launched Zorronet, a mobile application that integrates AI-powered command-and-control systems for field operators. The app consolidates data from various sources into a single platform, enhancing real-time decision-making and operational efficiency. Already in use across Israel, it aims to improve security operations by providing structured alerts and updates tailored to user roles.
Read more →PHGEZorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems AI-driven command and control platform applied in real-world railway operations, supporting broa
BiomX's subsidiary Zorronet has successfully completed a pilot project with Israel Railways, achieving a 98% success rate in preventing wildlife intrusions on railway tracks. Israel Railways has awarded Zorronet a framework supply agreement to install AI-powered detection systems. This technology aims to protect both wildlife and critical infrastructure, and there are plans to expand the deployment of this system across additional areas of the railway network. The initiative demonstrates the efficacy of real-time detection systems in infrastructure safety and ecological conservation.
Read more →PHGE▼ -9%on this news· ran to -32% by day 3shared move
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
BiomX Inc. has announced the acquisition of a controlling interest in DFSL, an Israeli defense engineering firm. This move aims to enhance BiomX's capabilities in the defense sector with DFSL's advanced LADAR technology, which improves real-time threat detection. The acquisition complements BiomX's existing AI command-and-control platform, Zorronet, and is expected to create a more integrated security solution. The deal is pending regulatory and shareholder approvals.
Read more →PHGEBiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications Targets $81B command-and-control and video analytics markets by 2030, driven by real-time situational aw
BiomX Inc. has completed the acquisition of Zorronet, an AI-powered command-and-control platform that unifies data from various sources for real-time decision-making in defense and security. This acquisition positions BiomX to enter the defense sector and build a portfolio that meets growing demand. Zorronet already has contracts with clients like the Israel Defense Forces and integrates advanced technologies for enhanced surveillance and response. The move is aligned with the strong market growth projected for command-and-control systems and video analytics by 2030.
Read more →PHGE▼ -16.4%on this news· ran to -32% by day 3
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
BiomX Inc. has entered an option agreement to acquire DFSL, a provider of LADAR technology for security and defense applications. The LADAR system aims to enhance detection while minimizing false alarms through its AI processing capabilities. This move marks BiomX's strategic entry into the rapidly growing counter-drone and security markets. The transaction depends on regulatory approvals and will involve a combination of cash, stock, and warrants for completion. Both the technology's real-world accuracy and market potential indicate promising opportunities ahead.
Read more →PHGEBiomX Adds Former Mossad Deputy to Advisory Board
BiomX Inc. has appointed Dr. Ehud Levi to its Advisory Board to explore strategic opportunities in security and defense, particularly in counter-UAS technologies. Dr. Levi brings over 30 years of experience in Israeli intelligence, having held significant roles in national security. His expertise is expected to guide BiomX in navigating the evolving landscape of unmanned systems and related threats.
Read more →PHGEBiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency Discloses "Going Concern" Explanatory Paragraph in Auditor's Report Netanya, Israel
BiomX Inc. (PHGE) has received a notification from NYSE American regarding non-compliance with its continued listing standards due to stockholders' equity deficiency. The company must submit a compliance plan by April 24, 2026, to address these issues. If the plan is not accepted or compliance is not established by September 25, 2027, it could face delisting. Additionally, the auditor's report includes a 'going concern' qualification, suggesting financial instability.
Read more →PHGEBiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
BiomX Inc. has launched a new subsidiary, X Security & Defense LTD., with an initial investment of over $3 million. This subsidiary aims to distribute advanced aerial firefighting systems in Israel, addressing the urgent need for rapid response capabilities in emergency situations. The move marks BiomX's entry into the growing defense and emergency response market, which is projected to expand significantly in the coming years.
Read more →PHGEBiomX CEO Issues Letter to Stockholders CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities Dover, DE
BiomX Inc. is undergoing significant strategic and financial restructuring, as outlined in a recent letter from its CEO to stockholders. The company is focusing on stabilizing its financial footing, simplifying capital structures, and positioning itself for future growth opportunities, particularly in sectors with strong global demand. Changes include an amendment to the warrant structure to alleviate potential overhangs and a review of non-essential costs to strengthen operations and management. The CEO emphasizes the necessity of these decisions for enhancing shareholder value and ensuring long-term viability.
Read more →PHGE▲ +44.4%on this news
BIOMX INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On
BiomX Inc. has announced the discontinuation of its Phase 2b clinical trial of BX004, a nebulized phage therapy aimed at treating cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. Following this decision, BiomX Israel commenced insolvency proceedings, leading to the appointment of a trustee and the termination of its Chief Executive Officer and Chief Financial Officer. As a result, the company declared a change of control and plans to deconsolidate BiomX Ltd. from its consolidated financial results, reflecting a significant shift in financial management and operational control.
Read more →PHGE▲ +69.5%on this news
BiomX Issues Statement Regarding Recent Common Stock Trading Activity
BiomX Inc. has issued a statement addressing unusual trading activity in its common stock. The company indicated that it is not aware of any material changes in its business that would explain this market behavior. Additionally, it will not comment further on market speculation or trading activity. BiomX focuses on developing phage therapies for chronic diseases caused by pathogenic bacteria.
Read more →PHGEBiomX Announces $3.0 Million Private Placement
BiomX Inc. has announced a private placement financing expected to generate approximately $3.0 million. The company will issue Series Y Convertible Preferred Stock and warrants to support its bacteriophage programs, including BX011 for Staphylococcus aureus infections. The financing is set to close on December 30, 2025, pending customary conditions.
Read more →PHGE▼ -36.9%on this news· ran to -53% by day 1
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX has announced the discontinuation of its Phase 2b BX004 trial for cystic fibrosis due to high rates of adverse events identified during a safety review. The decision follows recommendations from the Data Monitoring Committee and an internal analysis. The company will focus on its BX011 program for S. aureus infections while implementing cost-cutting measures, including workforce reductions.
Read more →PHGE▲ +5.4%on this news· ran to -23% by day 3
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
BiomX has announced progress in its Phase 2b trial of BX004 for cystic fibrosis, following a safety review by an independent Data Monitoring Committee (DMC) that recommended the study continue after adjustments to the dosing regimen. The company is addressing FDA inquiries regarding the nebulizer device used in the trial, which has led to a clinical hold on enrollment. Topline results from the updated trial protocol are now anticipated in Q2 2026. Despite current challenges, the company shows a strong commitment to developing therapies aimed at P. aeruginosa infections.
Read more →PHGE▲ +7.5%on this news· ran to -23% by day 3
BiomX Inc. Announces 1-for-19 Reverse Stock Split
BiomX Inc. has announced a 1-for-19 reverse stock split of its common stock, set to take effect on November 25, 2025. This decision, approved by stockholders earlier this month, aims to align the company's stock price more favorably in the market. The split will reduce the number of outstanding shares significantly while maintaining ownership percentages, though minor changes affecting fractional shares will occur. The company emphasizes its focus on advancing phage therapies to combat chronic diseases with unmet needs.
Read more →PHGEBiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
BiomX reported its third quarter 2025 financial results, highlighting positive FDA feedback for BX011 and anticipated feedback on BX004's clinical hold. The company noted significant advancements in regulatory discussions and plans to initiate a Phase 2a trial for BX011. Despite a net loss of $9.2 million, BiomX has sufficient cash to fund operations into early 2026.
Read more →PHGEBiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
BiomX Inc. (NYSE American: PHGE) will report its third quarter 2025 financial results and provide program updates on November 12, 2025, before U.S. markets open. A conference call and live audio webcast are scheduled for 8:30 a.m. ET on the same day. The company specializes in developing natural and engineered phage therapies to treat chronic diseases caused by specific pathogenic bacteria. Interested parties are encouraged to register for the call and can access the webcast through the company's website.
Read more →PHGE▼ -16.9%on this newsshared move
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
BiomX Inc. announced positive FDA feedback for its BX011 phage cocktail targeting Staphylococcus aureus in diabetic foot infections. This feedback supports the company's plan to advance BX011 into clinical trials, following a successful Phase 2 study of BX211 for diabetic foot osteomyelitis. The FDA's guidance indicates a clear regulatory path for BX011's development.
Read more →PHGEBiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX has provided an update on its BX004 Phase 2b trial, stating that it has successfully addressed FDA queries related to the nebulizer used for drug delivery. New FDA feedback indicates potential development pathways that could enhance BX004's clinical relevance. Patient enrollment in Europe is ahead of schedule, with topline results expected in early 2026.
Read more →PHGEBiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
BiomX Inc. announced that CEO Jonathan Solomon will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will highlight positive results from a Phase 2 trial of BX211, a phage therapy for chronic diabetic foot infections. Investors can request one-on-one meetings during the event.
Read more →PHGEBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
BiomX has announced a clinical hold on its Phase 2b trial for BX004, a treatment for cystic fibrosis, due to the FDA's review of a third-party nebulizer device. While the hold affects U.S. patient enrollment, trials in Europe continue as planned. BiomX remains optimistic that the hold will be lifted soon after submitting additional data.
Read more →PHGE▼ -11.7%on this news
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates Positive Phase 2 results for BX211 demonstrated 40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning unde
BiomX announced positive results from its Phase 2 trial of BX211, showing over 40% wound size reduction in diabetic foot osteomyelitis patients. The company also reported promising data for BX004, showcasing significant bacterial reduction without resistance. Despite a net loss in the second quarter of 2025 and declining cash reserves, BiomX plans to initiate a registrational study for BX211 and continues dosing patients in the Phase 2b trial for BX004. The company is expected to report topline results for BX004 by Q1 2026.
Read more →PHGE▲ +49.4%on this news
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
BiomX Inc. announced that it will report its second quarter 2025 financial results and provide program updates on August 13, 2025. The company, which specializes in phage therapies for chronic diseases, will host a conference call and live audio webcast to discuss these developments. Investors are encouraged to register for the call in advance to ensure connection and participation.
Read more →PHGEBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
BiomX has successfully initiated patient dosing in its Phase 2b trial for BX004, aimed at treating cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. The trial, enrolling approximately 60 patients, seeks to evaluate the therapy's efficacy over eight weeks. Previous trials indicate that 14.3% of participants achieved complete bacterial clearance after just ten days of treatment. The company anticipates FDA feedback by late 2025 which could expedite the approval process for this critical therapy.
Read more →PHGEBiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
BiomX has published promising results from its Phase 1b/2a trial of BX004, a phage therapy targeting antibiotic-resistant Pseudomonas aeruginosa infections in cystic fibrosis patients. The study showed a significant bacterial load reduction of approximately 500-fold compared to placebo, with no observed resistance. The company is now advancing to a Phase 2b trial, with results anticipated in early 2026.
Read more →PHGECorporate Presentation June 2025 Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance NYSE American: PHGE SAFE HARBOR STATEMENT About this Presentation The information contained in this pre
BiomX Inc. presented its clinical stage programs aimed at tackling antibiotic resistance, a significant global health challenge. The company highlighted positive results from Phase 2 studies on its phage therapy candidates, specifically targeting infections caused by S. aureus and P. aeruginosa. These therapies have shown promising efficacy and safety, marking a potential breakthrough in treating persistent infections resistant to standard antibiotics. BiomX positions itself as a leader in this emerging field with innovative approaches to phage therapy.
Read more →PHGEBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
BiomX Inc. announced that CEO Jonathan Solomon will present at the Biomed Israel 2025 conference, showcasing the topline Phase 2 results for its BX211 therapy designed for diabetic foot infections associated with Staphylococcus aureus. BX211 demonstrated safety and efficacy in reducing ulcer size and depth significantly compared to a placebo. The company received endorsements from key opinion leaders and aims to initiate a Phase 2/3 trial upon FDA feedback. This presentation marks an opportunity to highlight their progress in addressing antibiotic-resistant infections.
Read more →PHGEBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foo
BiomX reported its financial results for Q1 2025 and highlighted significant progress in its clinical programs. The company announced positive topline results for BX211, a phage therapy targeting diabetic foot osteomyelitis, which received positive feedback from industry experts. Additionally, BiomX has secured $12 million in financing to support ongoing and future clinical trials, including the upcoming Phase 2b study of BX004 in cystic fibrosis. The company expects sufficient funding to extend its operations into 2026, covering key upcoming milestones.
Read more →PHGEBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
BiomX Inc. will host a conference call and webcast on May 15, 2025, at 2:00 p.m. ET to report its financial results for the first quarter of 2025 and provide updates on its business and programs. The company specializes in developing natural and engineered phage therapies to target and combat harmful bacteria, addressing chronic diseases with significant unmet needs. The event aims to keep investors informed about the company's progress and financial health.
Read more →PHGE▼ -6.9%on this news
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) BX211 was safe and well-tolerated BX211 produced sustained and statistically significant
BiomX Inc. announced positive topline results from its Phase 2 trial evaluating BX211 for diabetic foot osteomyelitis (DFO). The trial showed that BX211 was safe and well-tolerated, with significant reductions in ulcer size, depth, and area. Following these results, BiomX is considering a Phase 2/3 trial, subject to FDA feedback. These findings highlight the potential of phage therapy in treating complex infections like DFO, where current treatment options are limited.
Read more →PHGE▼ -11.3%on this newsshared move
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Inc. has announced compliance with NYSE guidelines regarding its audit opinion disclosure. The company reported that its annual report for the fiscal year ended December 31, 2024, included a going concern qualification from its independent auditors. This disclosure is made to adhere to specific NYSE American Company Guide requirements and does not alter the existing financial statements. BiomX focuses on developing phage therapies aimed at treating chronic diseases caused by harmful bacteria.
Read more →PHGEBiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
BiomX announced positive topline results from its Phase 2 trial of BX211, a phage treatment for diabetic foot osteomyelitis. The trial demonstrated that BX211 was safe and well-tolerated, with significant reductions in ulcer size and depth compared to placebo. The findings are set to guide the company in planning a subsequent Phase 2/3 trial, pending FDA feedback. These results underscore the therapeutic potential of phage therapy in addressing severe bacterial infections.
Read more →PHGE▼ -7.2%on this news· ran to -17% by day 1
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million
BiomX reported its financial results for the fourth quarter and full year 2024, highlighting a $12 million financing to support ongoing clinical trials. The company anticipates topline results from the Phase 2 trial of BX211 by the end of the current quarter. Additionally, BiomX aims to reveal BX004 Phase 2b results in early 2026, reinforcing its financial strategy amidst rising R&D costs and recent impairments due to acquisitions. Despite a lower net loss compared to the previous year, the company is navigating challenges in its financial performance.
Read more →PHGEBiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
BiomX Inc. (NYSE American: PHGE) has announced that it will report its fourth quarter and full year 2024 financial results on March 25, 2025. The report will include business updates and the anticipated initial topline results from its Phase 2 trial for diabetic foot osteomyelitis. The company specializes in developing natural and engineered phage therapies aimed at treating chronic diseases with significant unmet medical needs, utilizing its proprietary BOLT platform for customization of treatments.
Read more →PHGE▼ -14%on this news· ran to -28% by day 3
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million Proceeds to support advancement of BX004 program through Phase 2b study topline results in cystic fibrosis (CF) patients, anticipated in
BiomX Inc. announced a series of financings expected to generate $12 million to support the advancement of its BX004 program through a Phase 2b study in cystic fibrosis (CF) patients. With topline results anticipated in Q1 2026, the funding is projected to facilitate the analysis of real-world evidence concerning P. aeruginosa reduction and its clinical outcomes. Notably, the financing involves noteworthy contributions from investors, including the Cystic Fibrosis Foundation. The company has previously received Fast Track and Orphan Drug Designations for BX004 from the FDA, indicating its potential therapeutic significance.
Read more →PHGEBiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
BiomX Inc. has confirmed its compliance with NYSE American's continued listing standards after addressing previous deficiencies. The NYSE American verified that the company met the necessary criteria for two consecutive quarters. BiomX specializes in developing phage therapies targeting pathogenic bacteria, which positions it within a niche area of substantial unmet medical needs. This development is a significant milestone for the company's stock market presence.
Read more →PHGEBiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline
BiomX has announced its third quarter financial results for 2024 and provided updates on its clinical programs, including BX211 for diabetic foot osteomyelitis (DFO). Patient enrollment for BX211 has been completed, with topline results expected in the first quarter of 2025. Additionally, the firm has resolved manufacturing delays in its BX004 program for cystic fibrosis (CF) and anticipates reporting results in the first half of 2026. Despite a decrease in cash reserves, the company remains optimistic, having secured additional funding and receiving positive feedback at scientific conferences.
Read more →PHGEBiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Inc. announced a conference call scheduled for November 14, 2024, to discuss its third quarter financial results and provide updates on business operations and programs. The company is focused on developing phage therapies targeting specific pathogenic bacteria, addressing chronic diseases with unmet needs. Investors can participate via a call or through a webcast available on the company's website.
Read more →PHGEBiomX Announces a Mandatory Unit Separation
BiomX Inc. has announced a mandatory separation of its trading units, which consist of common stock shares and warrants. This separation, effective on or about October 25, 2024, will see unit holders receive the underlying shares and warrants automatically. After this date, the shares will trade under the ticker symbol PHGE, integrating with existing shares of BiomX. The company continues to focus on advancing its therapeutic approaches against pathogenic bacteria.
Read more →PHGER e v ol u tioni z i n g the T r e a tme n t of I n f e c t i o n s A s s oci a t e d wit h C hr onic D iseas e Th r oug h P ha g e Th e r a p y INVE S T O R P R ES E N T A T I ON SEP T EM BE R 2 0 24 N Y S E Ameri c a n
BiomX Inc. is showcasing its innovative approach to treating chronic disease-related infections through phage therapy in a recent investor presentation. The company has reported positive outcomes in its BX004 clinical trials for cystic fibrosis and is progressing with its BX211 treatment for diabetic foot osteomyelitis. As antibiotic-resistant pathogens become increasingly challenging to manage, BiomX aims to offer viable and effective alternatives. The upcoming results for its pipeline therapies in late 2024 and early 2025 are highly anticipated in the biopharma sector.
Read more →PHGEBiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
BiomX Inc. announced it will present updated data from its Phase 1b/2a clinical trial of BX004, designed for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, at the upcoming North American Cystic Fibrosis Conference. The trial results indicate that patients receiving BX004 showed significant improvements, including a reduction in infection burden and better lung function compared to placebo. The findings will be showcased in both a poster presentation and a workshop discussion at the conference in Boston. BiomX is planning to initiate a Phase 2b trial next, following the promising results of the current study.
Read more →PHGEBiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BiomX Inc. (PHGE) will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024. CEO Jonathan Solomon's presentation will be available on-demand starting at 7:00 AM ET. BiomX focuses on developing novel natural and engineered phage therapies to target and eliminate pathogenic bacteria, addressing significant unmet medical needs. The company uses its proprietary BOLT platform for customizing phage treatments tailored to specific bacterial targets.
Read more →PHGE▼ -7.4%on this newsshared move
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024
BiomX Inc. will present data from its Phase 1b/2a study of the phage therapy BX004 at the upcoming European Respiratory Society Congress in Vienna. The study indicated that BX004 resulted in significant reductions of Pseudomonas aeruginosa in cystic fibrosis patients and improved lung function. CEO Jonathan Solomon noted the encouraging findings support their novel treatment approach for cystic fibrosis. Positive topline results from Part 2 of the trial were previously reported, further validating the therapy's potential.
Read more →PHGE▼ -11.6%on this news
BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX Inc. has announced a 1-for-10 reverse stock split, approved by stockholders on July 9, 2024. The split will reduce the number of outstanding shares from approximately 178.96 million to about 17.90 million, effective August 26, 2024. This action is intended to adjust the company's stock price and better align with market expectations.
Read more →PHGE▼ -11.6%on this news
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX Inc. reported its financial results for the second quarter of 2024, highlighting progress in its phage therapy pipeline. The company anticipates key clinical results in 2025 for two assets: BX004 and BX211, targeting cystic fibrosis and diabetic foot osteomyelitis, respectively. Notably, BiomX presented favorable outcomes from its Phase 1b/2a trial for BX004, and its net income has shown a positive shift to $4.5 million. The stockholder vote to convert preferred shares to common stock has implications for future investments and ownership structure.
Read more →PHGEBiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
BiomX Inc. will host a conference call on August 15, 2024, to discuss its second quarter financial results along with business and program updates. The call will take place at 8:00 a.m. ET, and interested parties can join via specific dial-in numbers or through a live audio webcast. BiomX specializes in developing personalized phage therapies targeting harmful bacteria, utilizing its proprietary BOLT platform to customize treatments for chronic diseases.
Read more →PHGE▼ -5.3%on this news
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
BiomX Inc. announced that the NYSE American accepted its plan to regain compliance with listing standards following a deficiency notification. The plan grants the company until November 23, 2025, to meet the requirements. BiomX's common stock will continue to be traded on the exchange during this period. The company intends to implement measures, including obtaining shareholder approval for stock conversion, to adhere to the plan.
Read more →PHGE▲ +8.2%on this news
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
BiomX Inc. announced that stockholders have voted to approve the conversion of Series X Non-Voting Convertible Preferred Stock into common stock. This decision aligns with the company's efforts to improve its financial standing and regain compliance with NYSE listing requirements. Following the conversion, significant increases in common stock are expected, bolstering the company's equity position. The CEO expressed optimism regarding the company's future potential, particularly with two advanced clinical candidates nearing critical development milestones.
Read more →PHGE▲ +19.4%on this news
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BiomX Inc. has received a notice from NYSE American regarding non-compliance with listing standards due to stockholders' equity deficiency. The company is required to submit a compliance plan by June 22, 2024, to regain compliance by November 23, 2025. Despite this notice, BiomX's common stock will remain listed on the NYSE American, although it will carry a designation indicating it is below compliance. The company is also exploring financial reclassifications that could help address its equity deficiency.
Read more →PHGE▲ +19.4%on this news
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
BiomX Inc. announced it will present data from its Phase 1b/2a clinical trial of BX004 at two upcoming conferences. The study focuses on the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections, revealing positive outcomes concerning safety and efficacy. Future clinical developments include a randomized, double-blind, placebo-controlled Phase 2b trial set to begin in Q4 2024. BiomX has also secured FDA Fast Track and Orphan Drug Designations for BX004.
Read more →PHGE▲ +6.9%on this news
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX Inc. has reported its first quarter 2024 financial results following its merger with Adaptive Phage Therapeutics. The company now has a cash runway extended through the fourth quarter of 2025 and anticipates key data readouts for its lead programs, BX004 and BX211, in 2025. Both candidates target serious chronic infections linked to specific bacteria, with BX004 showing early successes in clinical trials. However, the company reported a substantial increase in net loss and operating cash usage compared to the previous year, signaling financial pressure despite growing advancements.
Read more →PHGEBiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
BiomX Inc. will host its first quarter 2024 financial results conference call on May 21, 2024, at 8:00 a.m. ET. During the call, the company will report on its financial results and provide updates on its business and programs. BiomX specializes in developing phage therapies aimed at targeting specific pathogenic bacteria, addressing significant chronic diseases with unmet medical needs.
Read more →PHGE▲ +6.3%on this news
BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BiomX Inc. will participate in the RBC Capital Markets Global Healthcare Conference scheduled for May 15, 2024, in New York City. Chief Business Officer Assaf Oron will present the company’s innovative approaches to phage therapies targeting specific pathogenic bacteria. Attendees can access a live webcast of the presentation, which will be archived for future reference. This involvement signals BiomX's efforts to increase investor awareness and engagement.
Read more →PHGE▲ +17.4%on this news
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
BiomX Inc. announced that it will present data from the Phase 1b/2a study of its investigational drug BX004 at the upcoming ECCMID 2024. This treatment targets cystic fibrosis patients suffering from chronic pulmonary infections caused by Pseudomonas aeruginosa. The study has received acclaim as a 'Top Poster,' highlighting its significance in the field. Positive results from earlier trial phases suggest potential benefits, yet the company acknowledges various risks and uncertainties surrounding future clinical trial outcomes.
Read more →PHGE▲ +5.6%on this news· ran to +24% by day 3shared move
BiomX Announces the Appointment of Susan Blum to its Board of Directors
BiomX Inc. has announced the appointment of Susan Blum to its Board of Directors, who will also serve as chair of the audit committee. Blum brings nearly two decades of experience in finance and accounting within the life sciences sector, including her role as CFO at Melinta Therapeutics. CEO Jonathan Solomon expressed enthusiasm about her joining the board during a pivotal time for BiomX, highlighting her ability to guide the company in optimizing resources and advancing clinical-stage programs. The company is focused on developing natural and engineered phage therapies for chronic diseases.
Read more →PHGE▼ -8.9%on this newsshared move
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Clos
BiomX has reported its financial results for the fourth quarter and full year 2023, highlighting significant advancements in its clinical programs. The recent acquisition of Adaptive Phage Therapeutics has strengthened BiomX's position in the phage therapy market, adding a promising Phase 2 asset, BX211. The company is on track with patient recruitment for the BX211 Phase 2 trial in Diabetic Foot Osteomyelitis, while also planning further trials for its BX004 asset, which has shown effectiveness in Cystic Fibrosis patients. A financing round has provided critical capital to advance its clinical trials through 2025.
Read more →PHGE▲ +6.1%on this news· ran to +34% by day 1
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
BiomX Inc. has announced a conference call and webcast scheduled for April 3rd, 2024, at 8:00 a.m. ET, to report its fourth quarter and full year 2023 financial results. The call will also provide a business update outlining the company's advancements in phage therapies. BiomX focuses on targeting and destroying pathogenic bacteria, further promoting its role as a clinical-stage innovator in chronic disease treatment. The event will be accessible via phone and the company’s website for investors.
Read more →PHGEBiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Inc. has announced the successful completion of its acquisition of Adaptive Phage Therapeutics, establishing itself as a leader in phage therapy with a promising pipeline. The company raised $50 million through a private placement to support the development of its product candidates BX004 and BX211, which are targeting serious bacterial infections. Both therapies are entering Phase 2 clinical trials, with readouts expected in 2025. The acquisition and financing signify an important step for BiomX in addressing unmet medical needs in treating chronic pulmonary infections and diabetic foot osteomyelitis.
Read more →PHGE▲ +197.7%on this news
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX has entered a merger agreement with Adaptive Phage Therapeutics, aiming to form a prominent player in phage therapy. The merger will combine BiomX's and APT's resources, creating a strong pipeline with two Phase 2 assets targeting chronic pulmonary infections and diabetic foot osteomyelitis. Concurrently, BiomX secured a $50 million private placement financing to support the advancement of these assets through upcoming clinical trials. This transaction is backed by significant investment from reputable funds and is expected to close within the next 30 days.
Read more →PHGE▲ +197.7%on this news
FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT BIOMX INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this " Agreement "), dated as of March [ ], 2024, is made by and among BiomX Inc., a Delaware corporation (" Parent "), Ad
BiomX Inc. has entered into a stockholder support agreement as part of its merger strategy with Adaptive Phage Therapeutics, Inc. This agreement is a prerequisite for the completion of a planned merger involving BiomX and its subsidiaries. The details provided focus on the structure of the agreement and the obligations of the stockholders, especially regarding shares and warrants. The document serves as a foundation for the execution of the merger agreement.
Read more →PHGEBiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
BiomX Inc. has announced that its phage therapy, BX004, has been granted Orphan Drug Designation by the FDA for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. This designation reflects a significant unmet need in the patient population. The announcement follows positive topline results from a Phase 1b/2a trial, which suggest BX004 may offer improved treatment options compared to existing therapies.
Read more →PHGEItem 8. Financial Statements and Supplementary Data CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 CONTENTS Page REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C.P.A.s , PCAOB ID
BiomX Inc. recently released its consolidated financial statements as of December 31, 2022, revealing ongoing financial struggles. The reports indicate significant recurring losses and a decline in stockholders' equity, raising substantial doubts about the company's ability to sustain operations. With cash flow issues being a concern, financial adjustments arising from this uncertainty are not encapsulated within the current statements.
Read more →PHGE▼ -13.7%on this news
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
BiomX Inc. (NYSE American: PHGE) will host a virtual Key Opinion Leader event on December 4, 2023, to discuss the positive topline results from Part 2 of its Phase 1b/2a trial of BX004 for patients with cystic fibrosis and Pseudomonas aeruginosa infections. The event will feature discussions by leading specialists in phage therapy and updates from BiomX's CEO on the trial results. BX004 aims to address unmet medical needs in managing chronic pulmonary infections in cystic fibrosis patients, having recently received Fast Track designation from the FDA.
Read more →PHGE▼ -46.4%on this newsshared move
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BiomX Inc. announced positive topline results from Part 2 of its Phase 1b/2a trial evaluating BX004 for treating chronic pulmonary infections in cystic fibrosis patients. The trial showed significant improvements in pulmonary function and a notable reduction in P. aeruginosa levels among treated patients. BX004 was well-tolerated with no severe adverse events reported. The company plans to progress to a pivotal Phase 2b/3 trial, emphasizing the trial's encouraging outcomes for the cystic fibrosis community.
Read more →PHGE▼ -46.4%on this newsshared move
Revolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / November 2023 2 Safe Harbor Statement This presentation contains certain "forward - looking statemen
BiomX is showcasing its BOLT Phage therapy platform aimed at treating cystic fibrosis (CF) with chronic Pseudomonas aeruginosa infections. The lead program, BX004, has exhibited clinically meaningful improvements in pulmonary function compared to a placebo in a Phase 1b/2a trial. The company plans to advance BX004 into a larger pivotal Phase 2b/3 study based on promising initial results, positioning it to address a significant unmet need in CF. With strong backing from notable biotech investors and an estimated market potential exceeding $1 billion, BiomX is poised to impact the treatment landscape for CF patients.
Read more →PHGEBiomX Reports Third Quarter 2023 Financial Results and Provides Business Update Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA
BiomX Inc. reported its financial results for the third quarter of 2023, highlighting ongoing clinical trials for its product BX004. The company announced it expects to release part two data from its Phase 1b/2a trial later this month. In August, BX004 received Fast Track designation from the FDA, supporting its potential in treating chronic infections in cystic fibrosis patients. Despite the positive trial data presented, the company is dealing with significant financial losses.
Read more →PHGEBiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
BiomX Inc. will present data from its Phase 1b/2a study of BX004, aimed at treating chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients, at the upcoming North American Cystic Fibrosis Conference. The presentation will take place on November 3, 2023, and the abstract has been selected for oral presentation. The ongoing study aims to evaluate the safety and efficacy of BX004, with results from Part 2 of the trial anticipated soon. BiomX's research is crucial as it focuses on a major health issue affecting cystic fibrosis patients.
Read more →PHGEBiomX Announces the Appointment of Edward L. Williams to its Board of Directors
BiomX Inc. has appointed Edward L. Williams to its Board of Directors. Williams is recognized for his extensive commercial and board experience in the pharmaceutical industry, having previously held senior positions at Ascendis Pharma and Novo Nordisk. His expertise is expected to aid BiomX in advancing its novel phage therapies towards the market. The company specializes in targeting pathogenic bacteria to develop treatments for chronic diseases.
Read more →PHGEBiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BiomX Inc. announced the completion of patient dosing in Part 2 of its Phase 1b/2a study for BX004, targeting chronic pulmonary infections in cystic fibrosis patients. Results from this part of the trial are expected in November 2023. Part 1 data has been positively received in various presentations, indicating strong interest in the program. The FDA has granted BX004 Fast Track designation for treating Pseudomonas aeruginosa infections, further supporting its potential impact on patient care.
Read more →PHGEBiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
BiomX Inc. announced that it will present data from its ongoing Phase 1b/2a study of BX004, a phage therapy aimed at treating chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients. The presentation will take place during the European Respiratory Society International Congress 2023 in Milan, Italy, where the results of the initial part of the study will be discussed. BX004 aims to address a significant cause of morbidity and mortality in cystic fibrosis. Further results from the Phase 1b/2a study are expected in November 2023.
Read more →PHGEBiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
BiomX Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO Jonathan Solomon will lead the presentation, showcasing the company's advancements in phage therapies targeting specific pathogenic bacteria. The conference offers opportunities for engagement, including a webcast and chances for investor meetings.
Read more →PHGE▼ -9.3%on this news
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grant
BiomX reported its financial results for the second quarter of 2023 and provided updates on its BX004 clinical program, which targets cystic fibrosis. The company successfully completed patient screening for Part 2 of a Phase 1b/2a trial, with enrollment expected to exceed initial estimates. Notably, BX004 received Fast Track designation from the FDA. Financially, the company had a net loss of $6.4 million, a decrease compared to the previous year, partially due to a restructuring that reduced R&D expenses.
Read more →PHGEBiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
BiomX Inc. will host a conference call and live webcast on August 9, 2023, at 8:00 a.m. ET to report its second quarter financial results and provide business updates. This event aims to engage with investors and provide insights into the company's progress with its phage therapies targeting specific pathogenic bacteria. Interested parties can participate in the call or access the webcast through BiomX's website.
Read more →PHGE▲ +13.6%on this news· ran to +32% by day 1
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)
BiomX Inc. has announced that it will present data from its ongoing Phase 1b/2a study evaluating its phage therapy candidate, BX004, aimed at treating chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients. This presentation will take place at the Late-Breaking Science Session of the 46th European Cystic Fibrosis Conference in Vienna from June 7-10, 2023. The company has previously gained FDA clearance to begin this study, and results from Part 2 are anticipated in the third quarter of 2023.
Read more →PHGE▲ +7.2%on this news
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis ("CF"); Res
BiomX Inc. (PHGE) reported positive results from Part 1 of its ongoing Phase 1b/2a trial of BX004, a treatment for lung infections in cystic fibrosis. The trial demonstrated that BX004 was safe and well-tolerated, resulting in notable reductions in bacterial counts. The company has secured $7.5 million in financing, extending its cash runway into the third quarter of 2024. Looking ahead, results from Part 2 of the trial are expected in Q3 2023. Additionally, new board members were appointed to enhance the company's governance.
Read more →PHGE▲ +10%on this newsshared move
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
BiomX Inc. has announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors. These appointees bring significant experience in the life sciences sector, which is expected to aid the company in navigating financial and regulatory challenges as it advances its lead program, BX004, aimed at treating cystic fibrosis. Mr. Marks has held various senior legal positions, while Mr. Dambach has extensive experience in financial management within leading biotech firms.
Read more →PHGEBiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023
BiomX Inc. has announced a conference call and audio webcast scheduled for May 15, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and provide business updates. The company focuses on developing natural and engineered phage therapies aimed at treating chronic diseases by targeting specific bacteria. Stakeholders and interested parties are invited to participate in the call, and archived audio will be available on the company's website.
Read more →PHGE▲ +7.2%on this newsshared move
BiomX Announces Second Closing of $7.5 Million Private Placement
BiomX Inc. has successfully completed the second closing of a $7.5 million private placement to fund its clinical programs, especially BX004 aimed at treating lung infections in cystic fibrosis patients. This funding followed an initial closing held earlier in the year and was contingent on shareholder approval. The company plans to utilize the net proceeds for further clinical development and general corporate purposes. BiomX's commitment to filing a registration statement with the SEC further supports its financial strategy and operations.
Read more →PHGEBiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibro
BiomX Inc. reported its financial results for Q4 and the full year of 2022, announcing positive results from Part 1 of its ongoing Phase 1b/2a trial of BX004 for treating lung infections in cystic fibrosis patients. The trial showed excellent safety and reductions in bacterial load. The company is proceeding with patient enrollment for Part 2, with results expected in the third quarter of 2023 and anticipates a cash runway through mid-2024.
Read more →PHGE▲ +7%on this newsshared move
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
BiomX Inc., a clinical-stage company specializing in phage therapies, has announced a conference call scheduled for March 29th, 2023. During this call, they will report their fourth quarter and full year 2022 financial results along with providing business updates. BiomX focuses on developing treatments for chronic diseases by targeting specific pathogenic bacteria through natural and engineered phage compositions.
Read more →PHGEBiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BiomX announced positive results from Part 1 of its Phase 1b/2a study evaluating BX004 for treating chronic pulmonary infections in cystic fibrosis patients. The study demonstrated that BX004 was safe and well-tolerated, with preliminary efficacy signals showing a notable reduction in Pseudomonas aeruginosa bacterial burden. BiomX has commenced Part 2 of the study, where results are expected later in the third quarter of 2023. The positive findings mark an important step for phage therapy advanced by BiomX in treating persistent infections in CF patients.
Read more →PHGERevolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / Jan 2023 2 Safe Harbor Statement This presentation contains certain "forward - looking statements" w
BiomX is advancing a unique BOLT phage therapy platform aimed at treating cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa lung infections. The lead program, BX004, is expected to show safety and efficacy results from its Phase 1b/2a study in early 2023, with significant backing from investors including Johnson & Johnson and the CF Foundation. With over 17,000 CF patients affected by chronic infections in the U.S. and Western Europe, BX004 presents a major opportunity in a market expected to exceed $10 billion.
Read more →PHGEBiomX Announces $7.5 Million Private Placement
BiomX Inc. has announced a private placement of $7.5 million through a securities purchase agreement with select institutional and individual investors. The company plans to use these funds to support clinical development of BX004, aimed at treating lung infections in cystic fibrosis patients, along with other programs and operational costs. The financing will occur in two parts, with the first closing expected soon and the second contingent on stockholder approval. The securities involved have not yet been registered, limiting their sale unless exempt under relevant laws.
Read more →PHGE▲ +6.5%on this news
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan So
Read more →PHGEBiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023 Announced Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administe
Read more →PHGEDATED NOVEMBER 9, 2022 E xhibit 99.1 BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung I
Reports Third Quarter 2022 Financial Results and Provides Business Update Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023 Announced Publication in C
Read more →PHGEBiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company
Read more →PHGE▼ -6.4%on this news
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update Enrollment Continues in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis ("CF"); results from Part 1 expected b
Reports Second Quarter 2022 Financial Results and Provides Business Update Continues in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis ("CF"); results from Part 1 expected by the end of Q3 2022 into Second Collaboration with Boehringer Ingelheim t
Read more →PHGEBiomX LTD. All rights reserved Company Introduction Safe Harbor Statement This presentation contains certain "forward - looking statements" within the meaning of the "safe harbor" provisions of the U . S . Private Securi
Safe Harbor Statement This presentation contains certain "forward - looking statements" within the meaning of the "safe harbor" provisions of the U . S . Private Securities Litigation Reform Act of 1995 . Forward - looking statements can be identified by words such as : "target,"
Read more →PHGE▼ -6.1%on this news· ran to -18% by day 3
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update Upcoming KOL Webinar Scheduled for May 12 th to Discuss BX004 in Cystic Fibrosis IND Accepted to Conduct Clinical Testing of BX005 for the T
Reports First Quarter 2022 Financial Results and Provides Business Update KOL Webinar Scheduled for May 12th to Discuss BX004 in Cystic Fibrosis Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis Runway Through Multiple Data Readouts Will Hos
Read more →PHGEBiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Expecting Readouts from Part I of the Phase 1b/2a Cystic Fibrosis Study in the Third Quarter of 2022 and the Phase 1/2 Atopic
Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Expecting Readouts from Part I of the Phase 1b/2a Cystic Fibrosis Study in the Third Quarter of 2022 and the Phase 1/2 Atopic Dermatitis Study in the Fourth Quarter of 2022 Strong Balance
Read more →PHGEBiomX Presenting at Two Upcoming Conferences in November
Jefferies London Healthcare Conference on November 18 - 19, 2021 2021 Phage Futures Congress Europe on November 23 - 24, 2021 NESS ZIONA, Israel, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company a
Read more →PHGEBiomX Reports Third Quarter 2021 Financial Results and Provides Business Update Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 20
Reports Third Quarter 2021 Financial Results and Provides Business Update Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022 Cash Runway Now Extended to End of 2023, Well Beyond Key 2
Read more →PHGEBiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company
Read more →PHGEBiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
12-Week Study of BX001 Meets Safety and Tolerability Endpoints Statistically Significant Improvement from Baseline Observed in Appearance of Acne-prone Skin but No Meaningful Difference Demonstrated Relative to Vehicle Subject Satisfaction Questionnaire Outcomes Indicate Prefer
Read more →PHGEBiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced to
Read more →PHGEBiomX to Present at Upcoming September Investor Conferences
BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou
Read more →PHGEBiomX Reports Second Quarter 2021 Financial Results and Provides Business Update Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023 Expecting Four Clinical Data Readouts by Mid-
BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023 Clinical Data Readouts by Mid-2022 Host a Conference Call and Webcast Today at 8:00 am ET NESS ZIONA, Israel - Aug 16,
Read more →PHGEBiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021
NESS ZIONA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company
Read more →PHGEBiomX Inc. Announces $15 Million Registered Direct Offering
NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today it has entered i
Read more →PHGEBiomX Reports First Quarter 2021 Financial Results and Provides Business Updates - Company announces completion of enrollment for Phase 2 cosmetic clinical study of BX001 for acne-prone skin with results from 8-week trea
BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates NESS ZIONA, Israel -- May 24, 2021 -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that
Read more →PHGEBiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease
NESS ZIONA, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that that the Com
Read more →PHGEBiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Initiated Phase 2 cosmetic clinical study for BX001 in subjects with acne-prone skin; results expected from 8-week treatmen
BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Initiated Phase 2 cosmetic clinical study for BX001 in subjects with acne-prone skin; results expected from 8-week treatment period in Q3 2021 - Results from Phase 2 proof-of-conce
Read more →PHGEto "we," "us," and "our" refer to BiomX Inc. and its wholly-owned Israeli subsidiary, BiomX Ltd. and RondinX Ltd., an Israeli company and wholly-owned subsidiary of BiomX Ltd. Restated Risk Factors An investment in our s
the context otherwise requires, references in this Exhibit 99.1 to "we," "us," and "our" refer to BiomX Inc. and its wholly-owned Israeli subsidiary, BiomX Ltd. and RondinX Ltd., an Israeli company and wholly-owned subsidiary investment in our securities carries a significant d
Read more →PHGEBiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates Company unveils BOLT (BacteriOphage Lead to Treatment) platform designed for more rapid and efficient develo
BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates Company unveils BOLT (BacteriOphage Lead to Treatment) platform designed for more rapid and efficient development of phage therapy BOLT enables the Company to expan
Read more →PHGEBiomX Reports Second Quarter 2020 Financial Results and Provides Business Update - Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expec
Reports Second Quarter 2020 Financial Results and Provides Business Update Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expected by the end of 2020 On track for Phase 2 cosmetic clinical st
Read more →PHGEBiomX Reports First Quarter 2020 Financial Results and Provides Business Update Positive Phase 1 cosmetic clinical study results of BX001 in acne-prone skin reported; planned advance to Phase 2 study with readout expecte
Reports First Quarter 2020 Financial Results and Provides Business Update Phase 1 cosmetic clinical study results of BX001 in acne-prone skin reported; planned advance to Phase 2 study with readout expected in the second quarter of 2021 BX002 Phase 1 clinical study readout in
Read more →PHGEBiomX Announces Date of 2020 Annual Meeting of Stockholders Ness Ziona, Israel
BiomX Announces Date of 2020 Annual Meeting of Stockholders Ness Ziona, Israel - April 7, 2020 - BiomX Inc. (the "Company") (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced t
Read more →PHGEBiomX Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin BX001 demonstrates excellent safety, tolerability, and a statistically significant reduction of C. acnes levels on ski
Announces Positive Topline Data from Phase 1 Study Lead Candidate BX001 for Acne-Prone Skin demonstrates excellent safety, tolerability, and statistically significant reduction of C. acnes levels on skin to host conference call at 8:00 a.m. Eastern Time (U.S.) Ziona, Israel
Read more →PHGEBiomX Announces Dual Listing on the Tel-Aviv
BiomX Announces Dual Listing on the Tel-Aviv - Tel Aviv Stock Exchange trading effective February 6th, - BiomX common shares will continue to trade on the NYSE under the symbol PHGE Ness Ziona, Israel - February 3rd , 2020 - BiomX Inc. (NYSE: PHGE), a clinical-stage biotechno
Read more →PHGEBIOMX LTD. INDEX TO FINANCIAL STATEMENTS Page Interim Consolidated Balance Sheets as of
INDEX TO FINANCIAL STATEMENTS Page Interim Consolidated Balance Sheets as of September 30, 2019 (unaudited) and December 31, 2018 (audited) F-2 Interim Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited) F-4 Interim
Read more →PHGEBiomX Appoints Russell G.
BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director Russell G. Greig, Ph.D., BiomX's new Chairman of the Board of Directors Lynne Sullivan, BiomX's new Board Ness Ziona, Israel - November 4, 2019, - BiomX Inc. (N
Read more →PHGEChardan Healthcare Acquisition Corp. Completes Merger with BiomX Ltd. Combined company renamed BiomX Inc. will trade on the NYSE American stock exchange under the symbol PHGE beginning
Healthcare Acquisition Corp. Completes Merger with BiomX Ltd. company renamed BiomX Inc. will trade on the NYSE American stock exchange under the symbol PHGE beginning October 29, 2019 YORK and Ness Ziona, Israel, October 28, 2019 -- Chardan Healthcare Acquisition Corp. (NYSE:
Read more →PHGEChardan Healthcare Acquisition Corp. Shareholders Approve Definitive Merger Agreement with BiomX Ltd. - Combined Company Expected to Be Listed on the NYSE American Stock Exchange Under Symbols PHGE, PHGE.U, and PHGE.WS -
Chardan Healthcare Acquisition Corp. Shareholders Approve Definitive Merger Agreement with BiomX Ltd. - Combined Company Expected to Be Listed on the NYSE American Stock Exchange Under Symbols PHGE, PHGE.U, and PHGE.WS - NEW YORK and Ness Ziona, Israel, October 23, 2019 -- Ch
Read more →PHGEChardan Healthcare Acquisition Corp. Announces Amendment to Merger Agreement with BiomX Ltd. News provided by Chardan Healthcare Acquisition Corp.
Healthcare Acquisition Corp. Announces Amendment to Merger Agreement Chardan Healthcare Acquisition Corp. Oct 14, 2019, 07:30 ET NEW YORK and NESS ZIONA, Israel, Oct. 14, 2019 /PRNewswire/ -- Chardan Healthcare Acquisition Corp. (NYSE: CHAC, "CHAC"), a special purpose acquis
Read more →PHGEChardan Healthcare Acquisition Corp. Announces Amendment to Merger Agreement with BiomX Ltd. NEW YORK and
Healthcare Acquisition Corp. Announces Amendment to Merger Agreement with BiomX Ltd. NESS ZIONA, Israel, October 11, 2019 /PRNewswire/ -- Chardan Healthcare Acquisition Corp. (NYSE: CHAC, "CHAC"), a special purpose acquisition company ("SPAC") sponsored by affiliates of Chardan
Read more →PHGEChardan Advises Health Sciences Acquisitions Corporation on Merger with Immunovant
Chardan Advises Health Sciences Acquisitions Corporation on Merger with Immunovant NEW YORK, Oct. 3, 2019 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as M&A and Capital Markets Advisor for Health Sciences Acquisitions Corporation's (
Read more →PHGEChardan Healthcare Acquisition (CHAC) to merge with BiomX Ltd.
Chardan Healthcare Acquisition (CHAC) to merge with BiomX Ltd. to create a publicly - listed company focused on phage therapies for larger, attractive chronic disease markets BiomX develops natural and engineered phage cocktails designed to target and destroy harmful bacteria tha
Read more →PHGEBiomX Hosting Key Opinion Leader Symposium on Novel Phage Product for Acne Prone Skin
NESS ZIONA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that it will host a Key Opinion Leader (KOL) meeting on a novel phage product for acne prone skin on Friday, September 1
Read more →PHGEChardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd. - Combined Company Expected to Be Listed on the NYSE American Stock Exchange - - Joint Investor Conference Call Scheduled for
Chardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd. - Combined Company Expected to Be Listed on the NYSE American Stock Exchange - - Joint Investor Conference Call Scheduled NEW YORK and Ness Ziona, Israel, July 17, 2019 -- Chardan Healthcare Acq
Read more →PHGEChardan Healthcare Acquisition Corp. INDEX TO BALANCE SHEET Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 - F-9 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC
Healthcare Acquisition Corp. Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 - F-9 OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM the Shareholders and Board of Directors of Healthcare Acquisition Corp. on the F
Read more →Competitive Position
How PHGE ranks across every disease it competes inCompetitive Position is a premium feature
See how PHGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial